Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 181

The DOI matches its Crossref record.

Long‐term follow‐up of a prospective, double‐blind, placebo‐controlled randomized trial of clodronate in multiple myeloma

Open access
McCloskey, Eugene V., Dunn, Janet A., Kanis, John A., MacLennan, Ian C. M., Drayson, Mark T., the Medical Research Council Working Party on Leukaemia in Adults · 2001 · British Journal of Haematology

Abstract

Oral clodronate (1600 mg/d) has been shown to significantly reduce the incidence of skeletal complications in multiple myeloma. Preliminary analysis of a double‐blind placebo‐controlled trial of this treatment indicated that clodronate might prolong survival in patients without vertebral fractures at presentation. This issue was re‐examined after further follow‐up of the patients recruited into the Medical Research Council (MRC) VIth Myeloma Study. The trial examined the effects of clodronate on the natural history of skeletal disease in multiple myeloma; 619 patients were randomized between June 1986 and May 1992 commencing 15 d after the start of ABCM [adriamycin, BCNU (carmustine), cyclophosphamide, melphalan] chemotherapy or 43 d after ABCMP (ABCM + prenisolone); 535 patients who received clodronate or placebo were included in the analysis. The presence or absence of spinal fractures was assessed centrally from spinal X‐rays; long‐bone fractures were assessed locally. With a median follow‐up of 8·6 years, there was no overall significant difference in survival between the two treatment groups (O/E, χ 2 = 0·78,P = 0·38). Among the subgroup of 153 patients with no skeletal fractures at presentation there was a significant survival advantage (O/E, χ 2 = 7·52,P = 0·006) in favour of the 73 patients receiving clodronate, with median survivals being, respectively, 59 months (95% CI 43–71 months) and 37 months (95% CI 31–52 months), and 5‐year survivals being 46% and 35%. The original analysis of this study shows that there is a benefit in taking 1600 mg clodronate daily for patients with myelomatosis to prevent the development of new skeletal disease. Bearing in mind the limitations of subgroup analysis, the present study indicates that treatment may prolong survival in patients without overt skeletal disease at diagnosis. These observations, however, require confirmation in prospective clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2141.2001.02851.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 181

Metadata

Authors
McCloskey, E. V., Dunn, J. A., Kanis, J. A., MacLennan, I. C. M., Drayson, M. T., & the Medical Research Council Working Party on Leukaemia in Adults
Venue
British Journal of Haematology
Publisher
Wiley
Published
2001-06
Volume
113
Issue
4
Pages
1035-1043
ISSN
  • 0007-1048 (ISSN-L)
  • 1365-2141
OpenAlex
W2035237112
Cited by
181
References
0
FWCI
5.42
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long‐term follow‐up of a prospective, double‐blind, placebo‐controlled randomized trial of clodronate in multiple myeloma. https://app.cochat.ai/papers/10.1046/j.1365-2141.2001.02851.x
The paper
McCloskey, E. V., Dunn, J. A., Kanis, J. A., MacLennan, I. C. M., Drayson, M. T., & the Medical Research Council Working Party on Leukaemia in Adults. (2001). Long‐term follow‐up of a prospective, double‐blind, placebo‐controlled randomized trial of clodronate in multiple myeloma. British Journal of Haematology. https://doi.org/10.1046/j.1365-2141.2001.02851.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.